CGON - NASDAQ

CG Oncology, Inc. Common stock

CGON·NASDAQ

$54.42

-0.85%

HealthcareBiotechnology

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$4.80B

EPS-2.0800

P/E Ratio-26.16

Earnings Date08/07/2026

791.59M

Assets

3Y+436.0%

5Y+1249.0%

10Y+1249.0%

38.99M

Total Liabilities

82%

3Y+73.0%

5Y+111.0%

10Y+111.0%

752.60M

Total Equity

3Y+501.0%

5Y+1770.0%

10Y+1770.0%

CG Oncology, Inc. Common stock Funding & Solvency Profile

CGON · NASDAQ

Current Assets

Cash & Cash Equivalents32.49M

Net Receivables688.00K

Inventory1.56M

Other Current Assets15.07M

Total Current Assets759 M

Non-Current Assets

Property, Plant & Equipment19.57M

Goodwill & Intangible Assets10.87M

Long-Term Investments0.00

Other Non-Current Assets1.68M

Total Non-Current Assets21 M

Total Assets

791.59M

Financial Health Analysis

Current Ratio

24.63x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.05x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

729 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

96% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

CG Oncology, Inc. Common stock Balance Sheet

CGON • NASDAQ

CG Oncology, Inc. Common stock Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	32.5M	257.1M	8.3M	88.1M	53.6M
Short-Term Investments	709.7M	484.9M	179.4M	55.3M	0.0
Cash & Short-Term Investments	742.2M	742M	187.7M	143.5M	53.6M
Net Receivables	688K	781K	92K	303K	2K
Other Receivables	688K	781K	92K	303K	2K
Inventory	1.6M	0.0	0.0	0.0	0.0
Other Current Assets	15.1M	11.4M	6.4M	3.4M	4.8M
Total Current Assets	759.5M	754.2M	194.1M	147.2M	58.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	19.6M	493K	491K	506K	200K
Goodwill	10.3M	0.0	0.0	0.0	0.0
Intangible Assets	575K	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	10.9M	0.0	0.0	0.0	0.0
Other Non-Current Assets	1.7M	94K	4.7M	33K	85K
Total Non-Current Assets	32.1M	587K	5.2M	539K	285K
Total Assets	791.6M	754.8M	199.3M	147.7M	58.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5.7M	6.5M	3.2M	985K	1M
Accounts Payable	5.7M	6.5M	3.2M	985K	1M
Accrued Expenses	0.0	14.2M	9.7M	5.1M	824K
Short Term Debt	915K	0.0	569K	9M	2.9M
Capital Lease Obligations (Current)	0.0	186K	217K	189K	72K
Other Current Liabilities	24.2M	436K	547K	173K	1.1M
Total Current Liabilities	30.8M	21.4M	14.3M	15.4M	6M
NON-CURRENT LIABILITIES
Long Term Debt	6.1M	0.0	0.0	6.5M	12.1M
Deferred Tax Liabilities (Non-Current)	307K	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	1.7M	0.0	13K	352K	351K
Total Non-Current Liabilities	8.2M	52K	257K	7.1M	12.5M
Capital Lease Obligations	0.0	238K	461K	446K	122K
Total Liabilities	39M	21.4M	14.5M	22.6M	18.4M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	307.9M	202.9M	82.9M
Common Stock	8K	8K	0.0	0.0	0.0
Additional Paid-In Capital	0.0	951.4M	6.8M	3.6M	3.3M
Retained Earnings	-379M	-218M	-129.9M	-81.3M	-45.9M
Other Total Stockholders' Equity	1.1B	0.0	0.0	0.0	0.0
Total Stockholders' Equity	752.6M	733.4M	184.8M	125.2M	40.3M
Total Equity	752.6M	733.4M	184.8M	125.2M	40.3M
SUMMARY
Total Liabilities & Equity	791.6M	754.8M	199.3M	147.7M	58.7M
Total Investments	709.7M	484.9M	179.4M	55.3M	0.0
Total Debt	7M	238K	1M	15.9M	15.1M
Net Debt	-25.5M	-256.8M	-7.2M	-72.2M	-38.5M
Shares Outstanding	74,965,517	74,965,517	74,965,517	74,965,517	74,965,517

SEC Filings

CGON - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 26, 2026	May 20, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 08, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 08, 2026	May 08, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 24, 2026	April 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 13, 2026	April 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 27, 2026	February 27, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 27, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 13, 2026	January 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 09, 2026	January 09, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 26, 2025	November 22, 2025	2025	View Filing

Showing 1 to 10 of 44 filings

Related Guides

Blog Categories

Continue your CGON research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.